Left Ventricular Hypertrophy in CKD Patients

NCT07380893 | Not Yet Recruiting DMC

• 1 other identifier: Soh-Med--25-11-7MS
• Study Type: observational
• Target: 100
• Locations: 0 countries
• Sites: N/A

Brief Summary

The goal of this observational study is to determine the prevalence of left ventricular hypertrophy among patients with chronic kidney disease at Sohag University Hospital and assess the effect of erythropoietin therapy on left ventricular mass and geometry in anemic CKD patients. The main question it aims to answer is: Does erythropoietin therapy mitigate or even reverse LVH and improve cardiac geometry ?

Conditions

Left Ventricular Hypertrophy

Outcome Measures

Primary Outcomes (1)

• Change in LVMI following erythropoietin therapy in anemic CKD patients.

  - baseline transthoracic echocardiography will be performed for all group study.

Secondary Outcomes (1)

• Association between hemoglobin level and LVMI.

  6 months of erythropoitin therapy , transthoracic echocardiography will be performed for all group study.

Interventions

transthoracic echocardiography RADIATION

Standard transthoracic echocardiography will be performed for all participants, measuring: * Left ventricular end-diastolic diameter (LVEDD) * Interventricular septal thickness (IVSD) * Posterior wall thickness (PWD) * Left ventricular mass (LVM) * Left ventricular mass index (LVMI = LVM/body surface area)

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

study population is adults age (18-75)years, diagnosed with CKD stage 3-5 .

You may qualify if:

• Adults (≥18 years) diagnosed with CKD stages 3-5.
• Stable clinical condition for ≥3 months.
• Anemia (Hb \<10 g/dL) for cohort phase.
• Willingness to participate and provide informed consent.

You may not qualify if:

• Valvular or ischemic heart disease.
• Uncontrolled hypertension (BP \>180/110 mmHg).
• Acute coronary syndrome or decompensated heart failure in the past 3 months.
• Malignancy or active infection

Sponsors & Collaborators

• Sohag University: lead

MeSH Terms

Conditions

Hypertrophy, Left Ventricular

Condition Hierarchy (Ancestors)

Cardiomegaly; Heart Diseases; Cardiovascular Diseases; Hypertrophy; Pathological Conditions, Anatomical; Pathological Conditions, Signs and Symptoms

Study Officials

• Amal Kh Ahmed, MD

  Sohag university- faculty of medicine - internal medicine department

  STUDY CHAIR

Central Study Contacts

khaled M Mohamedein, MBCHB

CONTACT

+201507290373; drkhaledmmm1984@gmail.com

Marwa Z Elsayed, MD

CONTACT

+201007100970

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: resident of internal medicine

Study Record Dates

• First Submitted: December 30, 2025
• First Posted: February 2, 2026
• Study Start: January 15, 2026
• Primary Completion (Estimated): June 15, 2026
• Study Completion (Estimated): July 15, 2026
• Last Updated: February 2, 2026

Record last verified: 2026-01